Larimar Therapeutics soars 70% after April fair value signal

Larimar Therapeutics (NASDAQ:LRMR) stock surged over 70% to $3.03 by late June 2025, validating Investing.com's Fair Value analysis which had identified it as significantly undervalued at $1.78 in April. This substantial gain for the clinical-stage biotech, driven by its promising nomlabofusp candidate for Friedreich's ataxia and robust fundamentals despite negative EBITDA, highlights the efficacy of comprehensive valuation methodologies in uncovering mispriced securities. Further catalysts include progress toward BLA submission and a maintained $21 JMP Securities price target, suggesting continued upside potential.

Analysis

Larimar Therapeutics (NASDAQ:LRMR), a clinical-stage biotechnology firm, demonstrated significant stock appreciation with a 70.22% surge from $1.78 on April 10, 2025, to $3.03 by late June 2025. This move validated an earlier undervaluation thesis, which was predicated on strong underlying fundamentals despite a challenging market performance and a negative EBITDA of -$105 million. The investment case was supported by a robust current ratio of 7.48, indicating strong short-term liquidity, and the potential of its lead drug candidate, nomlabofusp, for the rare disease Friedreich’s ataxia. Future growth catalysts remain prominent, including the company's progress toward a Biologics License Application (BLA) submission for nomlabofusp and potential regulatory easements from the FDA. Furthermore, a maintained bullish analyst rating from JMP Securities, with a $21 price target, suggests that substantial upside may still exist beyond the recent rally.

Key Decisions for Investors

• Given the substantial rally has validated the fundamental thesis, investors should now focus on forward-looking catalysts, particularly the BLA submission timeline for nomlabofusp and any FDA guidance.
• The $21 price target from JMP Securities implies significant remaining upside, warranting a review of valuation models to assess if the current price of $3.03 still offers an attractive entry point.
• Despite the positive momentum and a strong current ratio of 7.48, investors must remain cognizant of the inherent risks associated with a clinical-stage biotech, including its negative EBITDA and dependency on singular regulatory outcomes.